Asset profile
Resmetirom · Rezdiffra
Small molecule
Evidence outlook
Approved: MASH / NASH, Metabolic Dysfunction-Associated Steatohepatitis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
38 competitors in this universe: 1 direct rival (same mechanism and indication), 2 same-class, 35 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Resmetirom (Rezdiffra): this drug | Approved | Small molecule | Thyroid hormone receptor-beta | ||
| VK2809 | Phase 2 | Small molecule | Thyroid hormone receptor-beta | ||
| Elunetirom | Phase 2 | Small molecule | Thyroid hormone receptor-beta | ||
| ASC47 | Phase 1 | Small molecule | Thyroid hormone receptor-beta | ||
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| ALN-CIDEB | Phase 3 | RNA / oligonucleotide | CIDEB | ||
| Aramchol | Phase 3 | — | Stearoyl-CoA desaturase 1 (SCD1) | ||
| Denifanstat | Phase 3 | Small molecule | Fatty acid synthase (FASN), FASN | ||
| Efimosfermin | Phase 3 | Protein / enzyme therapeutic | FGF21 | ||
| Efimosfermin Alfa | Phase 3 | Protein / enzyme therapeutic | FGF21 receptor | ||
| Lanifibranor | Phase 3 | Small molecule | Peroxisome proliferator-activated receptors (PPARs), PPAR (pan-agonist) | ||
| Lobeglitazone (Duvie) | Phase 3 | Small molecule | PPAR-gamma | ||
| Namodenoson | Phase 3 | — | Adenosine A3 receptor | ||
| ORMD-0801 | Phase 3 | Peptide | Insulin receptor (basal) | ||
| Pemvidutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) |
…and 23 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(10 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2)
2027 (4)
March 2027 (1)
What to watch
October 2027 (1)
2028 (3)
January 2028 (1)
What to watch
February 2028 (1)
What to watch
August 2028 (1)
2029 (1)
July 2029 (1)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.